Relating to: prohibiting step therapy protocols for certain cancer drugs.

AB 774 prohibits health insurers and pharmacy benefit managers from requiring step therapy protocols for certain cancer treatments. Specifically, it bans forcing patients to try less expensive drugs first when a doctor prescribes a drug approved by the FDA for metastatic cancer (cancer that has spread) or a cancer-associated condition (symptoms or side effects from cancer treatment that worsen health if untreated). The ban applies only when the drug meets three evidence-based criteria: FDA approval, alignment with best medical practices, and support from peer-reviewed research. This directly affects patients with advanced cancer and their insurers, ensuring access to prescribed treatments without unnecessary barriers.